Do analysts recommend PBYI or ADMA?

ADMA Biologics has a consensus price target of $19.67, indicating a potential upside of 119.74%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts clearly believe ADMA Biologics is more favorable than Puma Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 ADMA Biologics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Do analysts rate CTMX or PBYI?

CytomX Therapeutics currently has a consensus price target of $12.10, suggesting a potential upside of 216.75%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CytomX Therapeutics is more favorable than Puma Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytomX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.91 Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer TRDA or PBYI?

Entrada Therapeutics presently has a consensus target price of $17.50, suggesting a potential upside of 126.68%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Entrada Therapeutics is more favorable than Puma Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entrada Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend PBYI or MAZE?

Maze Therapeutics has a consensus price target of $66.00, indicating a potential upside of 111.13%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Maze Therapeutics is more favorable than Puma Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Maze Therapeutics 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has preferable valuation and earnings, PBYI or AAPG?

Puma Biotechnology has higher revenue and earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Puma Biotechnology $227.18M 1.85 $31.11M $0.48 17.21 Ascentage Pharma Group International $82.10M 21.04 -$177.71M N/A N/A

Puma Biotechnology (PBYI) Competitors

$8.26 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$8.26 0.00 (0.00%)

As of 07/2/2026 05:41 PM Eastern

Compare

PBYI vs. ADMA, CTMX, TRDA, MAZE, and AAPG

Should you buy Puma Biotechnology stock or one of its competitors? MarketBeat compares Puma Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Puma Biotechnology include ADMA Biologics (ADMA), CytomX Therapeutics (CTMX), Entrada Therapeutics (TRDA), Maze Therapeutics (MAZE), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry.

How does Puma Biotechnology compare to ADMA Biologics?

Puma Biotechnology (NASDAQ:PBYI) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

ADMA Biologics has a consensus price target of $19.67, indicating a potential upside of 119.74%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts clearly believe ADMA Biologics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, ADMA Biologics had 28 more articles in the media than Puma Biotechnology. MarketBeat recorded 28 mentions for ADMA Biologics and 0 mentions for Puma Biotechnology. ADMA Biologics' average media sentiment score of 0.06 beat Puma Biotechnology's score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Puma Biotechnology	Neutral
ADMA Biologics	Neutral

ADMA Biologics has a net margin of 32.43% compared to Puma Biotechnology's net margin of 10.69%. ADMA Biologics' return on equity of 39.98% beat Puma Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
ADMA Biologics	32.43%	39.98%	28.08%

Puma Biotechnology has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

ADMA Biologics has higher revenue and earnings than Puma Biotechnology. ADMA Biologics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$227.18M	1.85	$31.11M	$0.48	17.21
ADMA Biologics	$509.86M	4.07	$146.93M	$0.68	13.16

61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 22.2% of Puma Biotechnology shares are held by company insiders. Comparatively, 3.9% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

ADMA Biologics beats Puma Biotechnology on 13 of the 16 factors compared between the two stocks.

How does Puma Biotechnology compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

In the previous week, CytomX Therapeutics' average media sentiment score of 0.00 equaled Puma Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
CytomX Therapeutics	Neutral
Puma Biotechnology	Neutral

Puma Biotechnology has higher revenue and earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$35.54M	18.29	-$17.37M	-$0.41	N/A
Puma Biotechnology	$227.18M	1.85	$31.11M	$0.48	17.21

67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 3.8% of CytomX Therapeutics shares are held by company insiders. Comparatively, 22.2% of Puma Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CytomX Therapeutics currently has a consensus price target of $12.10, suggesting a potential upside of 216.75%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CytomX Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Puma Biotechnology has a net margin of 10.69% compared to CytomX Therapeutics' net margin of -166.40%. Puma Biotechnology's return on equity of 20.30% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Puma Biotechnology	10.69%	20.30%	12.05%

CytomX Therapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Summary

Puma Biotechnology beats CytomX Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Puma Biotechnology compare to Entrada Therapeutics?

Entrada Therapeutics (NASDAQ:TRDA) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 9.5% of Entrada Therapeutics shares are held by insiders. Comparatively, 22.2% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Entrada Therapeutics has a beta of -0.26, meaning that its share price is 126% less volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

In the previous week, Entrada Therapeutics' average media sentiment score of 0.00 equaled Puma Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
Entrada Therapeutics	Neutral
Puma Biotechnology	Neutral

Entrada Therapeutics presently has a consensus target price of $17.50, suggesting a potential upside of 126.68%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Entrada Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Puma Biotechnology has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	11.79	-$143.75M	-$3.99	N/A
Puma Biotechnology	$227.18M	1.85	$31.11M	$0.48	17.21

Puma Biotechnology has a net margin of 10.69% compared to Entrada Therapeutics' net margin of -2,895.05%. Puma Biotechnology's return on equity of 20.30% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%
Puma Biotechnology	10.69%	20.30%	12.05%

Summary

Puma Biotechnology beats Entrada Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Puma Biotechnology compare to Maze Therapeutics?

Puma Biotechnology (NASDAQ:PBYI) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Maze Therapeutics has a consensus price target of $66.00, indicating a potential upside of 111.13%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Maze Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Puma Biotechnology has a net margin of 10.69% compared to Maze Therapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
Maze Therapeutics	N/A	-36.62%	-31.78%

61.3% of Puma Biotechnology shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by company insiders. Comparatively, 5.3% of Maze Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Puma Biotechnology has higher revenue and earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$227.18M	1.85	$31.11M	$0.48	17.21
Maze Therapeutics	$167.50M	10.33	-$131.12M	-$2.53	N/A

In the previous week, Maze Therapeutics had 8 more articles in the media than Puma Biotechnology. MarketBeat recorded 8 mentions for Maze Therapeutics and 0 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.00 beat Maze Therapeutics' score of -0.20 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Puma Biotechnology	Neutral
Maze Therapeutics	Neutral

Puma Biotechnology has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market.

Summary

Puma Biotechnology beats Maze Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Puma Biotechnology compare to Ascentage Pharma Group International?

Puma Biotechnology (NASDAQ:PBYI) and Ascentage Pharma Group International (NASDAQ:AAPG) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Puma Biotechnology has a net margin of 10.69% compared to Ascentage Pharma Group International's net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat Ascentage Pharma Group International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
Ascentage Pharma Group International	N/A	N/A	N/A

Puma Biotechnology has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

In the previous week, Ascentage Pharma Group International had 3 more articles in the media than Puma Biotechnology. MarketBeat recorded 3 mentions for Ascentage Pharma Group International and 0 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.00 beat Ascentage Pharma Group International's score of -0.35 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Puma Biotechnology	Neutral
Ascentage Pharma Group International	Neutral

Ascentage Pharma Group International has a consensus price target of $46.43, indicating a potential upside of 150.97%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, analysts clearly believe Ascentage Pharma Group International is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20

Puma Biotechnology has higher revenue and earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$227.18M	1.85	$31.11M	$0.48	17.21
Ascentage Pharma Group International	$82.10M	21.04	-$177.71M	N/A	N/A

61.3% of Puma Biotechnology shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Puma Biotechnology beats Ascentage Pharma Group International on 9 of the 15 factors compared between the two stocks.

Get Puma Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PBYI vs. The Competition

Export

Metric	Puma Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$420.43M	$3.78B	$7.18B	$12.47B
Dividend Yield	N/A	2.16%	2.66%	6.51%
P/E Ratio	17.21	21.61	28.02	24.70
Price / Sales	1.85	338.16	537.00	97.28
Price / Cash	9.90	147.12	49.26	57.09
Price / Book	3.19	8.66	10.96	6.46
Net Income	$31.11M	$23.81M	$3.57B	$337.01M
7 Day Performance	1.85%	3.39%	2.12%	1.69%
1 Month Performance	17.50%	10.81%	5.25%	3.81%
1 Year Performance	132.68%	62.61%	33.29%	23.90%

Puma Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PBYI Puma Biotechnology	0.8168 of 5 stars	$8.26 flat	N/A	+132.7%	$420.43M	$227.18M	17.21	200	News Coverage Analyst Upgrade Short Interest Increase Lockup Expiration
ADMA ADMA Biologics	4.4029 of 5 stars	$8.36 -0.2%	$19.67 +135.4%	-51.1%	$1.93B	$510.17M	12.27	530	Trending News Gap Down
CTMX CytomX Therapeutics	1.9697 of 5 stars	$3.82 +2.0%	$12.10 +217.2%	+53.4%	$647.57M	$76.20M	N/A	170	Positive News
TRDA Entrada Therapeutics	2.7609 of 5 stars	$7.57 -1.8%	$17.50 +131.1%	+6.7%	$294.45M	$25.42M	N/A	110
MAZE Maze Therapeutics	1.8216 of 5 stars	$29.48 +1.6%	$66.00 +123.9%	+171.8%	$1.63B	$20M	N/A	121	News Coverage Insider Trade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PBYI) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Puma Biotechnology (PBYI) Competitors

PBYI vs. ADMA, CTMX, TRDA, MAZE, and AAPG

How does Puma Biotechnology compare to ADMA Biologics?

Summary

How does Puma Biotechnology compare to CytomX Therapeutics?

Summary

How does Puma Biotechnology compare to Entrada Therapeutics?

Summary

How does Puma Biotechnology compare to Maze Therapeutics?

Summary

How does Puma Biotechnology compare to Ascentage Pharma Group International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBYI vs. The Competition

Puma Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Puma Biotechnology (PBYI) Competitors

PBYI vs. ADMA, CTMX, TRDA, MAZE, and AAPG

How does Puma Biotechnology compare to ADMA Biologics?

Do analysts recommend PBYI or ADMA?

Does the media refer more to PBYI or ADMA?

Is PBYI or ADMA more profitable?

Which has more volatility and risk, PBYI or ADMA?

Which has stronger earnings & valuation, PBYI or ADMA?

Do institutionals & insiders hold more shares of PBYI or ADMA?

Summary

How does Puma Biotechnology compare to CytomX Therapeutics?

Does the media refer more to CTMX or PBYI?

Which has preferable valuation & earnings, CTMX or PBYI?

Do insiders & institutionals hold more shares of CTMX or PBYI?

Do analysts rate CTMX or PBYI?

Is CTMX or PBYI more profitable?

Which has more volatility & risk, CTMX or PBYI?

Summary

How does Puma Biotechnology compare to Entrada Therapeutics?

Do institutionals and insiders believe in TRDA or PBYI?

Which has more volatility & risk, TRDA or PBYI?

Does the media refer more to TRDA or PBYI?

Do analysts prefer TRDA or PBYI?

Which has higher valuation and earnings, TRDA or PBYI?

Is TRDA or PBYI more profitable?

Summary

How does Puma Biotechnology compare to Maze Therapeutics?

Do analysts recommend PBYI or MAZE?

Is PBYI or MAZE more profitable?

Do institutionals & insiders have more ownership in PBYI or MAZE?

Which has stronger earnings and valuation, PBYI or MAZE?

Does the media refer more to PBYI or MAZE?

Which has more risk & volatility, PBYI or MAZE?

Summary

How does Puma Biotechnology compare to Ascentage Pharma Group International?

Is PBYI or AAPG more profitable?

Which has more risk & volatility, PBYI or AAPG?

Does the media prefer PBYI or AAPG?

Do analysts prefer PBYI or AAPG?

Which has preferable valuation and earnings, PBYI or AAPG?

Do institutionals & insiders believe in PBYI or AAPG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBYI vs. The Competition

Puma Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools